A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Active:	Yes
Cancer Type:	Prostate Cancer Unknown Primary	NCT ID:	NCT07543055
Trial Phases:	Phase I	Protocol IDs:	BPX-601-PSA-2540 (primary) NCI-2026-06250
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Regeneron Pharmaceuticals, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT07543055

Summary

This study will test a study drug called BPX-601, a CAR-T cell product manufactured from
the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601
is a drug that is only used in clinical studies.

The study is looking at:

- What side effects BPX-601 might cause

- What is the best dose of BPX-601

- How well BPX-601 may work to destroy prostate cancer

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.